234 related articles for article (PubMed ID: 16985695)
1. Bladder cancer 2000: molecular markers for the diagnosis of transitional cell carcinoma.
Chao D; Freedland SJ; Pantuck AJ; Zisman A; Belldegrun AS
Rev Urol; 2001; 3(2):85-93. PubMed ID: 16985695
[TBL] [Abstract][Full Text] [Related]
2. Urinary hyaluronic acid and hyaluronidase: markers for bladder cancer detection and evaluation of grade.
Lokeshwar VB; Obek C; Pham HT; Wei D; Young MJ; Duncan RC; Soloway MS; Block NL
J Urol; 2000 Jan; 163(1):348-56. PubMed ID: 10604388
[TBL] [Abstract][Full Text] [Related]
3. Immunocyt and the HA-HAase urine tests for the detection of bladder cancer: a side-by-side comparison.
Hautmann S; Toma M; Lorenzo Gomez MF; Friedrich MG; Jaekel T; Michl U; Schroeder GL; Huland H; Juenemann KP; Lokeshwar VB
Eur Urol; 2004 Oct; 46(4):466-71. PubMed ID: 15363562
[TBL] [Abstract][Full Text] [Related]
4. [Molecular markers for transitional cell carcinoma of bladder].
Kleinmann J; Siegel YI; Zisman A
Harefuah; 2003 Jul; 142(7):531-5, 565. PubMed ID: 12908389
[TBL] [Abstract][Full Text] [Related]
5. Urine cytology. It is still the gold standard for screening?
Brown FM
Urol Clin North Am; 2000 Feb; 27(1):25-37. PubMed ID: 10696242
[TBL] [Abstract][Full Text] [Related]
6. Biomarkers for non-muscle invasive bladder cancer: Current tests and future promise.
Darwiche F; Parekh DJ; Gonzalgo ML
Indian J Urol; 2015; 31(4):273-82. PubMed ID: 26604437
[TBL] [Abstract][Full Text] [Related]
7. [Hyaluronic acid and hyaluronidase. 2 new bladder carcinoma markers].
Hautmann SH; Schroeder GL; Civantos F; Duncan RC; Gnann R; Friedrich MG; Hellstern A; Huland H; Soloway MS; Lokeshwar VB
Urologe A; 2001 Mar; 40(2):121-6. PubMed ID: 11315586
[TBL] [Abstract][Full Text] [Related]
8. A side by side comparison of cytology and biomarkers for bladder cancer detection.
Schroeder GL; Lorenzo-Gomez MF; Hautmann SH; Friedrich MG; Ekici S; Huland H; Lokeshwar V
J Urol; 2004 Sep; 172(3):1123-6. PubMed ID: 15311054
[TBL] [Abstract][Full Text] [Related]
9. Current bladder tumor tests: does their projected utility fulfill clinical necessity?
Lokeshwar VB; Soloway MS
J Urol; 2001 Apr; 165(4):1067-77. PubMed ID: 11257640
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of a modified care protocol substituting bladder tumor markers for cystoscopy for the followup of patients with transitional cell carcinoma of the bladder: a decision analytical approach.
Lotan Y; Roehrborn CG
J Urol; 2002 Jan; 167(1):75-9. PubMed ID: 11743279
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of DD23 as a marker for detection of recurrent transitional cell carcinoma of the bladder in patients with a history of bladder cancer.
Gilbert SM; Veltri RW; Sawczuk A; Shabsigh A; Knowles DR; Bright S; O'Dowd GJ; Olsson CA; Benson MC; Sawczuk IS
Urology; 2003 Mar; 61(3):539-43. PubMed ID: 12639642
[TBL] [Abstract][Full Text] [Related]
12. Current concepts of tumor markers in bladder cancer.
Droller MJ
Urol Clin North Am; 2002 Feb; 29(1):229-34. PubMed ID: 12109349
[TBL] [Abstract][Full Text] [Related]
13. Urine markers for detection and surveillance of bladder cancer.
Xylinas E; Kluth LA; Rieken M; Karakiewicz PI; Lotan Y; Shariat SF
Urol Oncol; 2014 Apr; 32(3):222-9. PubMed ID: 24054865
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic value of voided urine and bladder barbotage cytology in detecting transitional cell carcinoma of the urinary tract.
Konety BR; Metro MJ; Melham MF; Salup RR
Urol Int; 1999; 62(1):26-30. PubMed ID: 10436427
[TBL] [Abstract][Full Text] [Related]
15. Urine-based biomarkers for the early detection and surveillance of non-muscle invasive bladder cancer.
Herman MP; Svatek RS; Lotan Y; Karakiewizc PI; Shariat SF
Minerva Urol Nefrol; 2008 Dec; 60(4):217-35. PubMed ID: 18923359
[TBL] [Abstract][Full Text] [Related]
16. Urinary markers in the everyday diagnosis of bladder cancer.
Dal Moro F; Valotto C; Guttilla A; Zattoni F
Urologia; 2013; 80(4):265-75. PubMed ID: 24419920
[TBL] [Abstract][Full Text] [Related]
17. Urine markers for bladder cancer surveillance: a systematic review.
van Rhijn BW; van der Poel HG; van der Kwast TH
Eur Urol; 2005 Jun; 47(6):736-48. PubMed ID: 15925067
[TBL] [Abstract][Full Text] [Related]
18. Comparison of human telomerase reverse transcriptase messenger RNA and telomerase activity as urine markers for diagnosis of bladder carcinoma.
Bialkowska-Hobrzanska H; Bowles L; Bukala B; Joseph MG; Fletcher R; Razvi H
Mol Diagn; 2000 Dec; 5(4):267-77. PubMed ID: 11172490
[TBL] [Abstract][Full Text] [Related]
19. A prospective evaluation of the diagnostic and potential prognostic utility of urinary human telomerase reverse transcriptase mRNA in patients with bladder cancer.
Bowles L; Bialkowska-Hobrzanska H; Bukala B; Nott L; Razvi H
Can J Urol; 2004 Dec; 11(6):2438-44. PubMed ID: 15636669
[TBL] [Abstract][Full Text] [Related]
20. Urinary markers of bladder carcinoma.
Dey P
Clin Chim Acta; 2004 Feb; 340(1-2):57-65. PubMed ID: 14734196
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
